Search Results - "Lopes, Eloisi Caldas"
-
1
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Published in Cancer cell (11-11-2019)“…Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic…”
Get full text
Journal Article -
2
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations
Published in Blood (16-08-2018)“…The biological role of extracellular vesicles (EVs) in diffuse large B-cell lymphoma (DLBCL) initiation and progression remains largely unknown. We…”
Get full text
Journal Article -
3
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Published in Proceedings of the National Academy of Sciences - PNAS (19-05-2009)“…Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified…”
Get full text
Journal Article -
4
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Published in The Journal of clinical investigation (01-10-2010)“…JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms (MPNs), following the discovery of activating JAK2 mutations in the…”
Get full text
Journal Article -
5
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab
Published in PloS one (25-01-2010)“…The positron-emitting radionuclide (89)Zr (t(1/2) = 3.17 days) was used to prepare (89)Zr-radiolabeled trastuzumab for use as a radiotracer for characterizing…”
Get full text
Journal Article -
6
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Published in The Journal of clinical investigation (01-12-2010)“…B cell lymphoma 6 (BCL6), which encodes a transcriptional repressor, is a critical oncogene in diffuse large B cell lymphomas (DLBCLs). Although a…”
Get full text
Journal Article -
7
Targeting heat shock protein 90 with non‐quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma
Published in Hepatology (Baltimore, Md.) (01-07-2009)“…The inhibition of heat shock protein 90 (Hsp90) has emerged as a promising antineoplastic strategy in diverse human malignancies. Hsp90 has been predicted to…”
Get full text
Journal Article -
8
Approaches to Targeting Cancer Stem Cells in Solid Tumors
Published in Current stem cell research & therapy (01-01-2019)“…CSCs are a population of self-renewing and tumor repopulating cells that have been observed in hematologic and solid tumors and their presence contributes to…”
Get more information
Journal Article -
9
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Published in Cell reports (Cambridge) (15-12-2015)“…Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from…”
Get full text
Journal Article -
10
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma
Published in Molecular oncology (01-03-2014)“…Ewing sarcoma is characterized by multiple deregulated pathways that mediate cell survival and proliferation. Heat shock protein 90 (HSP90) is a critical…”
Get full text
Journal Article -
11
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents
Published in Current opinion in investigational drugs (London, England : 2000) (01-06-2006)“…Heat shock protein (Hsp)90 is a chaperone with essential roles in maintaining transformation and in elevating the survival and growth potential of cancer…”
Get more information
Journal Article -
12
Disruption of mitochondrial membrane potential during apoptosis induced by PSC 833 and CsA in multidrug-resistant lymphoid leukemia
Published in Toxicology and applied pharmacology (15-08-2004)“…Previous findings from our laboratory demonstrated that when used at low concentration (0.1 μg ml −1), CsA as well as its analog PSC 833 were able to revert…”
Get full text
Journal Article -
13
Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma
Published in Blood (02-11-2023)“…We have previously described that diffuse large B-cell lymphomas (DLBCL) harboring an inflammatory and immunosuppressive microenvironment (i.e., IN-LME) carry…”
Get full text
Journal Article -
14
Abstract 7586: TOX loss-of-function(TOXLOF)results in BCR hyperactivation andenhanced responses to BCR-targeting in diffuse large B cell lymphomas (DLBCL)
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…Abstract DLBCL originate from germinal center B cells (GCB). The ABC-DLBCL subtype, characterized by activation of B-cell receptor (BCR) signaling and…”
Get full text
Journal Article -
15
The epichaperome is an integrated chaperome network that facilitates tumour survival
Published in Nature (London) (20-10-2016)“…Chaperomes are dynamic assemblies of proteins that regulate cellular homeostasis but specific cellular stresses remodel chaperome components into a stable…”
Get full text
Journal Article -
16
A novel tetrazole analogue of resveratrol is a potent anticancer agent
Published in Bioorganic & medicinal chemistry letters (15-01-2019)“…[Display omitted] •Tetrazolylresveratrols exhibit anti-cancer activity against human cancer cells.•Tetrazolylresveratrols are cytotoxic against MV4-11 cells…”
Get full text
Journal Article -
17
Ligaria cuneifolia flavonoid fractions modulate cell growth of normal lymphocytes and tumor cells as well as multidrug resistant cells
Published in Immunobiology (1979) (01-01-2005)“…Flavonoids are ubiquitous compounds present in plant extracts. They represent a major active component of the plant extract and are often known for their…”
Get full text
Journal Article -
18
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Published in Nature chemical biology (25-09-2011)“…The inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes. Affinity purification using PU-H71 reveals cancer-specific protein networks in…”
Get full text
Journal Article -
19
Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma
Published in Cancer research (Chicago, Ill.) (15-08-2020)“…Abstract Multiple myeloma (MM) is a plasma cell malignancy diagnosed in approximately 30 thousand patients per year and accounts for nearly 12 thousand deaths…”
Get full text
Journal Article -
20
Abstract 272: Novel role for eIF4E in homing of acute myeloid leukemia cells
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…Abstract Acute myeloid leukemia (AML) remains with dismal outcomes, mostly attributed to the inability of therapies to eliminate leukemia stem cells (LSCs)…”
Get full text
Journal Article